Shi Xu, Feng Dechao, Wei Wuran
Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Front Surg. 2021 Nov 15;8:753547. doi: 10.3389/fsurg.2021.753547. eCollection 2021.
Bladder cancer is the second-ranked tumor of the genitourinary system. Transurethral resection of bladder tumor (TURBT) is currently the most important diagnosis and treatment method for non-muscular invasive bladder cancer (NMIBC). However, due to its high recurrence and progression rate, as well as high cost and inapplicability to some patients, intravesical chemoablation as an alternative to TURBT may be promising for NMIBC patients. However, there are very little data comparing its effectiveness, safety, best effective drug type, dosage selection, and cost with TURBT at present, which deserves further evaluation. The present study was designed in order to discuss which treatment is superior to another between chemoablation and TURBT in patients with NMIBC. Databases including PubMed, MEDLINE, EMBASE, and Cochrane Library databases, as well as Chinese databases including CNKI (China national knowledge infrastructure), Wan Fang database, and Chinese Clinical Trial Registry, from August 1994 to the time when the official submission of this review was published was included in this review and screened by two reviewers (XS and DCF) independently. There were no language limitations. The study was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Data was analyzed using RevMan and Stata software. The primary aims were the clinical effectiveness, including response rate, complete response OS, CSM, recurrence rate, time to recurrent, progression rate, and time to progression, among others. The secondary aims mainly included safety and tolerability, including costs, operation time, hospital stay, bleeding volume, and complications, among others. This study is registered as PROSPERO CRD42021271124.
膀胱癌是泌尿生殖系统中排名第二的肿瘤。经尿道膀胱肿瘤切除术（TURBT）是目前非肌层浸润性膀胱癌（NMIBC）最重要的诊断和治疗方法。然而，由于其高复发率和进展率，以及高成本和对某些患者不适用，膀胱内化学消融作为TURBT的替代方法，对于NMIBC患者可能很有前景。然而，目前很少有数据将其有效性、安全性、最佳有效药物类型、剂量选择和成本与TURBT进行比较，这值得进一步评估。本研究旨在探讨在NMIBC患者中，化学消融和TURBT哪种治疗方法更具优势。本综述纳入了1994年8月至本综述正式提交发表时的数据库，包括PubMed、MEDLINE、EMBASE和Cochrane图书馆数据库，以及中国数据库，包括中国知网（CNKI）、万方数据库和中国临床试验注册中心，并由两名 reviewers（XS和DCF）独立筛选。没有语言限制。该研究按照系统评价和Meta分析的首选报告项目（PRISMA）进行。使用RevMan和Stata软件进行数据分析。主要目的是临床有效性，包括缓解率、完全缓解、总生存期（OS）、无复发生存期（CSM）、复发率、复发时间、进展率和进展时间等。次要目的主要包括安全性和耐受性，包括成本、手术时间、住院时间、出血量和并发症等。本研究注册为PROSPERO CRD42021271124。
